AMICUS THERA (NASDAQ:FOLD)
3.49
+0.05 (1.45%)
| AMICUS THERA (NASDAQ:FOLD) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $3.44 | 52 Week High | $13.50 | ||
| Open | $3.50 | 52 Week Low | $3.21 | ||
| Day High | $3.70 | P/E | N/A | ||
| Day Low | $3.43 | EPS | $-2.37 | ||
| Volume | 36,114 | ||||
| More FOLD Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| DEPO | 3 | REED | 2 |
| AVII | 2 | SCLN | 2 |
| SGEN | 2 | CRXX | 2 |
| FTBK | 2 | OPTV | 2 |
| KEG | 1 | MDP | 1 |
| MXIM | 1 | NVTL | 1 |
Entities who have mentioned FOLD
- Carl Icahn | View Related Stories »
- JPMorgan | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Deutsche Bank | View Related Stories »
- Needham & Company | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Lazard | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Trading Radar | View Related Stories »
- 13G | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- UBS | View Related Stories »
- Morgan Stanley | View Related Stories »
View All Major News StreetInsider.com Major News for FOLD
- Amicus Therapeutics (FOLD) Reports Better-Than-Expected Q2 Adj-Loss of $0.51
- Amicus Therapeutics (FOLD) Reports Smaller Than Expected Q1 Loss; Revs Light
View All ReportsStreetInsider.com Reports on FOLD
- Amicus Therapeutics (FOLD) Names CEO John Cowley to Chairman
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Unusual 11 Mid-Day Movers 10/05: ROIAK, DEPO, AVII, CMLS Higher; FOLD, SGEN, SCLN, REED Lower
- Lazard Capital Downgrades Amicus Therapeutics (FOLD) to Hold
- Wedbush Morgan Downgrades Amicus Therapeutics (FOLD) to Underperform; Slashes PT
View All Press ReleasesCompany Press Releases on FOLD
- Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
- Amicus Therapeutics to Announce Fourth Quarter and Year End 2009 Financial Results on February 16, 2010
- Amicus Therapeutics Outlines 2010 Strategic Priorities and Continued Progress with Product Pipeline
- Amicus Therapeutics to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
StreetInsider Reports on FOLD by Category
View All BlogsBlogs on FOLD
- Genzyme: Shire Chomping at the Bit
- Developments for Parkinson's Disease Ignite Investor Enthusiasm
- Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited
- Closing Bell: The bull returns ahead of earnings (GE, WFC, FOLD, CIEN, VG)
- Sell Genzyme Near Term Due to Challenges with Manufacturing Biologics
View All FilingsSEC Filings on FOLD
- Form 8-K AMICUS THERAPEUTICS INC For: Feb 05
- Form SC 13G AMICUS THERAPEUTICS INC Filed by: CHL Medical Partners II, L.P.
- Form 8-K AMICUS THERAPEUTICS INC For: Jan 11
Comments on FOLD
No comments are currently available.
